Acrux Ltd
Company Profile
Business description
Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone Topical Solution, and among others.
Contact
103-113 Stanley Street
West Melbourne
MelbourneVIC3003
AUST: +61 383790100
E: Joanna.johnson@acrux.com.au
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
36
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,910.50 | 348.80 | 4.61% |
| CAC 40 | 6,896.91 | 203.51 | -2.87% |
| DAX 40 | 19,670.88 | 609.38 | -3.00% |
| Dow JONES (US) | 40,608.45 | 62.52 | 0.15% |
| FTSE 100 | 7,705.87 | 204.66 | -2.59% |
| HKSE | 20,628.86 | 364.37 | 1.80% |
| NASDAQ | 17,124.97 | 574.37 | 3.47% |
| Nikkei 225 | 34,326.90 | 2,612.87 | 8.24% |
| NZX 50 Index | 12,183.27 | 376.72 | 3.19% |
| S&P 500 | 5,456.90 | 474.13 | 9.52% |
| S&P/ASX 200 | 7,708.90 | 333.90 | 4.53% |
| SSE Composite Index | 3,216.41 | 29.60 | 0.93% |